Key clinical point: Extended half-life clotting factors cut infusion frequency but cost much more.
Major finding: Extended half-life factor IX halved the number infusions, but increased the cost from $697,497 to more than $1 million in a year.
Study details: The study examined usage patterns in nearly 8,000 patients over 18 months.
Disclosures: The study was funded HTRS/ATHN Dataset Research Engagement and a DREAM Award from the Hemostasis and Thrombosis Research Society. Dr. Croteau reported consulting for Bayer, Bioverativ, Biomarin, CSL-Behring, and other companies.
Croteau SE et al. Haemophilia. 2019. doi: 10.1111/hae.13758.